TIGIT Emerges as New Target for Immune Checkpoint Blockade Strategies

Jane de Lartigue, PhD
Published: Wednesday, Feb 08, 2017
As researchers continue to identify a growing number of immune checkpoints as targets for anticancer therapy, the recently discovered TIGIT pathway is emerging as a promising new avenue for exploration.

Compugen Ltd is developing COM701, an antibody that targets PVRIG, another recently elucidated member of the PVR family. The company is planning to submit an Investigational New Drug application to the FDA during the fourth quarter of 2017.

Where TIGIT Fits In

The major effectors of the immune system are cytotoxic T cells, and these are activated in a 2-step process when they encounter antigen-presenting cells bearing foreign antigens. Antigens engage the T-cell receptor (TCR) on the surface of the T cell, but this signal is coupled with a second signal that determines whether the T cell is turned on or off. Together these costimulatory and coinhibitory signals are known as immune checkpoints.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication